Valuentum Exclusive Analysis for the Discerning Investor

Symbol Keyword

Jun 26, 2023

Latest Report Updates Concentrated in Mining & Chemicals and Healthcare Industries
In our 16-page equity research reports, we offer a fair value estimate for each company based on a rigorous and transparent discounted cash flow process, assess the attractiveness of a stock based on a firm-specific margin of safety, and provide a relative valuation comparison in the context of the company’s industry and peers. Each report includes detailed pro forma financial statements, explicit fundamental forecasts, and scenario analysis. A cross section of the ValueCreation and ValueRisk ratings provides a financial assessment of a company’s business quality (competitive position), while the ValueTrend and Economic Castle ratings offer insight into the trajectory of a firm’s economic profit creation (ROIC versus WACC). Included in each 16-page report is a company's rating on the Valuentum Buying Index (VBI), a methodology that combines rigorous financial and valuation analysis with an evaluation of a firm's technicals and momentum indicators to derive a score between 1 and 10 for each company (10=best). We believe the VBI methodology helps identify the most attractive stocks at the best time to consider buying, helping to avoid value traps and lagging performance due to the opportunity cost of holding a stock with great potential but at an inopportune time. The Best Ideas Newsletter portfolio puts the VBI into practice. Read more about the Valuentum Buying Index rating system, "Value and Momentum Within Stocks, Too." Members can access our 16-page company research reports by using our 'Symbol' search box in our website header.

May 23, 2023

Call Me Unconcerned
Image: Large cap growth has dominated returns the past five years. The Best Ideas Newsletter portfolio continues to have significant exposure to this area. We’re taking it slow this time of year. With the area of large cap growth nearly doubling since the beginning of 2018, trouncing the return of the broader market, dividend growth strategies, the area of small cap value and general REIT indices, it’s just hard to find much wrong with staying pat. The proliferation of artificial intelligence will likely propel big cap tech and large cap growth to new highs, while small cap value may continue to be weighed down by the banks--and dividend-oriented strategies may face continued pressure from rising interest rates and tired real estate markets. Things were a bit murky during 2022, but thanks for keeping the faith.

May 22, 2023

Nice! -- NASDAQ-100 Follows Through on Breakout
Image: NASDAQ-100 breaks through August 2022 resistance.

May 17, 2023

Our Reports on the Health Care Bellwethers Industry
Our reports on the Health Care Bellwethers industry can be found in this article. Reports include JNJ, CVS, ABT, ABBV, LLY, AMGN, MRK, PFE, VRTX, UNH, BMY, GILD, ISRG, MDT, WBA, ZTS.

Feb 3, 2023

Dividend Increases/Decreases for the Week of February 3
Let's take a look at firms raising/lowering their dividends this week.

Dec 27, 2022

Exclusive Call: What To Expect From Valuentum in 2023
Video: 2022 was a successful year by almost every measure from the simulated Best Ideas Newsletter portfolio and simulated Dividend Growth Newsletter portfolio to the simulated High Yield Dividend Newsletter portfolio and Exclusive publication and beyond. There were some disappointments in 2022, of course, but the year showed the value of a Valuentum membership. Join President of Investment Research Brian Nelson on this year's Exclusive conference call to learn what to expect from Valuentum in 2023. Cheers!

Dec 14, 2022

Moderna’s Personalized Cancer Vaccine (PCV) Could Be a Game-Changer When Combined with Merck’s KEYTRUDA
Image: Moderna’s therapeutics pipeline continues to advance, and the company recently received positive news regarding its personalized cancer vaccine (PCV), ID # mRNA-4157, when combined with Merck’s KEYTRUDA. Image Source: Moderna. Moderna and Merck have revealed what could be a big breakthrough with respect to investigational cancer treatment, but we remind investors that the news is a Phase 2b study, and there is still a meaningful probability that the Phase 3 trial for the immunotherapy may be unsuccessful. Still, the Phase 2b results for the PCV-KEYTRUDA combination showed an impressive 44% reduction in the risk of recurrence or death in patients with late-stage melanoma, and the adverse effects from the combined PCV-KEYTRUDA therapy occurred in just 14.4% of patients, which was not terribly different than those receiving KEYTRUDA alone. There are a plethora of players dabbling in mRNA vaccine technology these days, and we remain excited about its future potential to improve patient outcomes, as much as we are about CRISPR gene-editing technology.

Nov 30, 2022

Great Year for (Our) High Yield Dividend Ideas! Inquire about the High Yield Dividend Newsletter!
Image: The year-to-date simulated estimated performance of the High Yield Dividend Newsletter portfolio, which continues to hold up well during 2022, while offering an attractive forward estimated dividend yield. Simulated estimated performance is calculated by Valuentum and has not been externally audited. Inquire about the High Yield Dividend Newsletter. The next edition will be released December 1, 2022. Based on our estimates, the simulated High Yield Dividend Newsletter portfolio is down ~4.4% on a price-only basis so far in 2022 on an interim basis, using data from the trading session November 29 (retrieved from Seeking Alpha). By comparison, according to data from Morningstar, the Vanguard 60/40 stock/bond portfolio (VBIAX) is down more than 15% so far this year (on a price-only basis), the Vanguard Real Estate ETF (VNQ) is down 26% year-to-date (on a price-only basis), while the iShares Mortgage Real Estate Capped ETF (REM) is down ~30% on a year-to-date basis. Each simulated newsletter portfolio at Valuentum targets a different strategy, whether long-term capital appreciation, dividend growth, income/high yield, and the like. Generally, for the simulated Best Ideas Newsletter portfolio, it targets long-term capital appreciation potential (not in one year or a couple years, but in the long run). During the past five years...an ETF that tracks the area of large cap growth is up more than 70%, while an ETF that tracks the area of dividend growth has advanced ~40%, an ETF that tracks small cap value is up ~17% during the past five years, while an ETF that tracks the area of the highest-yielding S&P 500 companies is up just 12% -- according to data from Morningstar. REITs, as measured by the VNQ, are up just 3% over the past five years. We nailed the call on the drawdown in the 60/40 stock/bond portfolio this year, and readers should continue to question the merits of modern portfolio theory, not merely state that now the 60/40 stock/bond is cheap (after the huge decline)! It's extremely important to continue to test whether something makes sense or not. If interest rates continue to rise, we think bond prices will continue to face pressure. Sometimes, a few of our best ideas don't work out (as in any year), but that's why we use the simulated (and diversified) Best Ideas Newsletter portfolio to measure the success of the VBI. We're not a quant shop. We believe in the qualitative overlay. For example, there are highly-rated ideas that don't make the cut for the simulated Best Ideas Newsletter portfolio and there are low-rated ideas that find their way into the newsletter portfolio because they add a diversification benefit. Given the massive up years in the broader markets in 2019, 2020 and 2021, with the simulated Best Ideas Newsletter portfolio estimated to be down in the low-double-digits so far this year (approximately ~10%-12%, by our latest tally) -- and this estimate includes the missteps in Meta Platforms (META), PayPal (PYPL), and Disney (DIS) -- this is actually pretty awesome, in our view -- especially considering all that went wrong in other areas such as crypto, REITs, mortgage REITs, disruptive innovation stocks, Chinese equities, and the list goes on and on. A low double-digit estimated percentage decline, as that "experienced" in the simulated Best Ideas Newsletter portfolio so far in 2022 after huge up years, can be viewed as just part of a long-term journey that targets capital appreciation. For context, Berkshire Hathaway's stock price was nearly halved in 1974. It's okay to time the markets a bit as we did last August, but staying engaged with investing over the long haul is a key part of the recipe for success, as it was for Berkshire investors. For readers seeking income and high yield dividend ideas, please consider subscribing to our High Yield Dividend Newsletter. 2022 hasn't been an up year for a lot of investors, but it shouldn't have been a disaster either, and we've done a really great job avoiding the worst areas. We're interested in hearing how you are using our service, so that we can continue to get better. All told, we're excited about 2023, and we hope you are too!

Nov 28, 2022

2022 Showcased the Value of a Valuentum Membership
In bull markets, almost everyone is a winner. But 2022 was different. This year was a big test for Valuentum, and we passed with flying colors. We delivered across the board during the year from ideas in the Exclusive publication and the efficacy of the dividend growth methodology to the resilience of high yield ideas and simulated Best Ideas Newsletter portfolio relative performance--despite setbacks from Meta Platforms, PayPal, and beyond. Tune in to the latest video installment from Valuentum. Thanks for listening!

Nov 10, 2022

Market Whipsaw: Crypto Collapse and a Lower-than-Expected Inflation Print
Image: Uncertainty in the cryptocurrency markets has surged with concerns over the liquidity of a key exchange. Investors are weighing the spillover effects of crypto with the view that the pace of inflation may have peaked. The U.S. equity market continues to be highly volatile as it whipsaws between concerns over the health and sustainability of cryptocurrency and optimism over lower-than-feared inflation readings. We maintain our bearish/defensive stance on equities, but at the same time, we continue to be “fully-invested” across the simulated newsletter portfolios in part because we don’t want to miss out on days like today, November 10, when the markets are soaring ~2.5%-5.5% depending on which index you are monitoring. We’re also not ruling out a Santa Claus rally through the end of the year. Merry Dow Jones, as they say!